GCM
TEVA icon

Glaxis Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Glaxis Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-11,000
Closed -$633K – 41
2014
Q4 		$633K Buy
+11,000
New +$613K 1.36% 22

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Glaxis Capital Management's TEVA Position: Q1 2015 in Review

Glaxis Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2015, closing a stake of 11,000 shares — an estimated $633K sold.

Glaxis Capital Management first reported a position in TEVA in Q4 2014 and held it in 1 quarter. The position peaked at $633K in Q4 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q1 2015.

  • Glaxis Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Glaxis Capital Management sold 11,000 Teva Pharmaceuticals shares in Q1 2015, an estimated $633K.
  • Glaxis Capital Management first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Glaxis Capital Management's Teva Pharmaceuticals position peaked at $633K in Q4 2014.
  • 821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2015.

Based on Glaxis Capital Management's 13F filing for Q1 2015, filed 17 Apr 2015.